New publication in Biomaterials “A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity” – https://bit.ly/2Oj5uVm . In collaboration with Jenny Ting in the Lineberger Cancer Center.
In fall of 2019, Dr. Ainslie will become a standing member of the NIH study section NANO.
The talk “Acetalated Dextran: a spoonful of sugar helps the medicine (and vaccine) go down!” was given to a group at UGA in the Center for Vaccines and Immunology in Athens, GA.
Dr. Ainslie gives a talk on Acetlated Dextran and met with collegue Devika Manickam. It was great to hear about her work with non-viral gene carriers. Also a great dinner and conversation with her and Dr. Lauren O’Donnell at Grand … Read more
Congrats Elizabeth Gurysh on receiving a NIH NCI F32 for development of glioblastoma therapy with Drs. Shawn Hingtgen & Ryan Miller.
Drs. Bachelder and Jenny Ting were recently awarded a $6M RO1 for the development of a influenza vaccine.
Dr. Ainslie gave a talk at University of Sydney on Acetalated Dextran in the school of pharmacy. It was great to see the university and visit with my colleague Veysel Kayser and learn about his amazing work with antibodies.
As part of the PharmAlliance, Dr. Ainslie gave a talk on Host-Directed therapies and Dr. Bachelder on Universal Flu Vaccines. Here is the beautiful mural from their main hall.
Sad news all, my lab’s Google+ page will be shut down by Google in April. Not sure how I will break it to my three followers.
